Anixa Biosciences is trading 7.69% higher at $2.80 after positive breast-cancer vaccine Phase 1 data, survival observations from its ovarian-cancer CAR-T trial, and Dr. Carmen Guerra’s appointment to its Cancer Business Advisory Board on September 16, 2026.

  • The official release said the programs are advancing toward further clinical development.
  • Broader risk-on sentiment may also support the move, with major U.S. indices higher pre-market.